1. Home
  2. SNCR vs BCAB Comparison

SNCR vs BCAB Comparison

Compare SNCR & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Synchronoss Technologies Inc.

SNCR

Synchronoss Technologies Inc.

HOLD

Current Price

$8.78

Market Cap

101.3M

Sector

Technology

ML Signal

HOLD

Logo BioAtla Inc.

BCAB

BioAtla Inc.

HOLD

Current Price

$0.35

Market Cap

71.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNCR
BCAB
Founded
2000
2007
Country
United States
United States
Employees
802
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
101.3M
71.6M
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
SNCR
BCAB
Price
$8.78
$0.35
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$1.00
AVG Volume (30 Days)
152.3K
2.7M
Earning Date
03-10-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$170,909,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.07
N/A
52 Week Low
$3.98
$0.24
52 Week High
$12.85
$1.43

Technical Indicators

Market Signals
Indicator
SNCR
BCAB
Relative Strength Index (RSI) 75.33 35.34
Support Level $8.60 $0.29
Resistance Level $8.73 $0.37
Average True Range (ATR) 0.11 0.06
MACD -0.08 0.00
Stochastic Oscillator 68.29 22.36

Price Performance

Historical Comparison
SNCR
BCAB

About SNCR Synchronoss Technologies Inc.

Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Share on Social Networks: